Related Experiment Videos
BRAF alterations are associated with complex mutational profiles in malignant melanoma
Maria Daniotti1, Maria Oggionni, Tiziana Ranzani
1Unit of Melanoma Genetics, Istituto Nazionale per lo Studio e la Cura dei Tumori, via Venezian 1, 20133 Milan, Italy.
Oncogene
|June 15, 2004
Summary
This study analyzed BRAF and other gene mutations in 41 melanoma samples, revealing distinct mutational profiles. Certain profiles, like p16/ARF loss with BRAF mutations, correlate with patient survival, suggesting molecular classification impacts melanoma management.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Melanoma exhibits diverse mutational landscapes.
- Understanding these profiles is crucial for targeted therapies and prognosis.
Purpose of the Study:
- To investigate the mutational profiles of key genes (BRAF, RAS, PTEN, TP53, CDKN2A, CDK4) in human melanoma.
- To correlate these profiles with clinical behavior and patient survival.
Main Methods:
- Analysis of short-term melanoma cell lines derived from 41 patient biopsies.
- Genomic analysis of BRAF, RAS, PTEN, TP53, CDKN2A, and CDK4 genes and their expression.
Main Results:
- Identified novel missense mutations in BRAF, PTEN, CDKN2A, and CDK4.
- Activating BRAF mutations and loss of p16/ARF were frequent. PTEN alterations, NRAS, and TP53 mutations were less common.
- p16/ARF loss with BRAFV599E mutation was the most prevalent profile. Specific co-occurrences of mutations (e.g., TP53/PTEN with BRAF) and associations (e.g., PTEN loss with CDKN2A/TP53 in BRAF-wildtype) were observed.
Conclusions:
- Distinct molecular subgroups of melanoma exist, characterized by specific mutational profiles.
- These molecular classifications correlate with different clinical behaviors and survival outcomes.
- A comprehensive molecular classification of melanoma could significantly improve clinical management and treatment strategies.